Cross-sectional study assessing long-term safety of interferon-β-1b for relapsing-remitting MS
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Objective: The 16-Year Long-Term Follow-Up (LTF) to the pivotal interferon-β-1b (IFNβ-1b) trial explored clinical, MRI, cognitive, and patient-reported outcomes. Here, we report the safety assessments.
Methods: In the pivotal study, 372 patients were randomized to placebo (n = 123), IFNβ-1b 50 μg (n = 125), or IFNβ-1b 250 μg (n = 124) subcutaneously every other day for up to 5 years. Sixteen years later, patients were asked to participate in this cross-sectional follow-up study. No particular therapy was stipulated during follow-up. Adverse events experienced since the pivotal trial were recorded. Neutralizing antibodies (NAbs) to IFNβ-1b were measured using the myxovirus protein A induction assay. Statistical analyses were descriptive.
Results: In total, 88.2% of patients (328/372) were identified. Some centers achieved 100% ascertainment, obviating selection bias. Treatment-related adverse events (e.g., leukopenia and liver and thyroid dysfunction) reported by LTF participants were in keeping with those previously established. Based on a follow-up period that includes 2,000 patient-years of IFNβ-1b treatment, no new adverse events were observed that were associated with long-term IFNβ-1b exposure. By LTF, NAbs to IFNβ-1b disappeared in the majority (76%) of NAb-positive patients. NAb status during the pivotal study appeared to have no impact on long-term clinical and MRI outcomes. There were more deaths among patients assigned to placebo in the pivotal study (20/109 [18.3%]) compared with patients who received IFNβ-1b 50 μg (9/108 [8.3%]) or IFNβ-1b 250 μg (6/111 [5.4%]).
Conclusion: The results from the 16-Year Long-Term Follow-Up study support the long-term safety of interferon-β-1b therapy in multiple sclerosis.
Classification of evidence: This study provides Class III evidence that patients with relapsing-remitting MS taking IFNβ-1b 50 μg or 250 μg subcutaneously every other day for up to 5 years, with subsequent unspecified treatment, have fewer deaths after 16 years of follow-up than similar patients on placebo for up to 5 years, with subsequent unspecified treatment (risk difference 11.5%, 95% confidence interval 4–19).
Glossary
- AE=
- adverse event;
- BOD=
- burden of disease;
- CI=
- confidence interval;
- EDSS=
- Expanded Disability Status Scale;
- EQ-5D=
- European Quality of Life–5-Dimensional questionnaire;
- IFN=
- interferon;
- LTF=
- Long-Term Follow-Up;
- MS=
- multiple sclerosis;
- MSFC=
- Multiple Sclerosis Functional Composite;
- MSSS=
- Multiple Sclerosis Severity Score;
- NAbs=
- neutralizing antibodies;
- RRMS=
- relapsing-remitting multiple sclerosis;
- SPMS=
- secondary progressive multiple sclerosis.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Long-term Safety and Efficacy of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease
Dr. Marianne de Visser and Dr. Maudy Theunissen
► Watch
Topics Discussed
Alert Me
Recommended articles
-
Articles
Interferon β-1b–neutralizing antibodies 5 years after clinically isolated syndromeH.-P. Hartung, M.S. Freedman, C.H. Polman et al.Neurology, August 17, 2011 -
Articles
A reassessment of the plateauing relationship between T2 lesion load and disability in MSMaria Pia Sormani, Marco Rovaris, Giancarlo Comi et al.Neurology, September 30, 2009 -
Articles
Interferon beta-1b in secondary progressive MSResults from a 3-year controlled studyThe North American Study Group on Interferon beta-1b in Secondary Progressive MS et al.Neurology, November 22, 2004 -
ARTICLES
Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1bExperience during the first three years et al.Neurology, October 01, 1996